Underestimating The Moat: Why McKesson's Oncology Pivot And Share Buybacks Signal Structural Upside

Dividendos Portugal 73 Followers Follow Summary McKesson operates within a US pharma distribution oligopoly, generating $5B+ in FCF and aggressively repurchasing shares. The oncology segment is driving growth, with a 31% YoY revenue increase and strategic acquisitions reinforcing the shift toward higher-margin businesses. Despite negative shareholder equity from buybacks and opioid liabilities, MCK maintains strong liquidity, low leverage, and disciplined capital returns. I rate MCK a 'Buy' for its compounding EPS growth, oncology expansion, and undervalued DCF versus market-implied risk premium. David Tran/iStock Editorial via Getty Images The Investment Thesis in Two Sentences McKesson ( MCK ) is a pharmaceutical distributor operating within a three-player oligopoly that controls 90% of the US market. It generates over $5B in FCF and is slowly transforming into a This article was written by Dividendos Portugal 73 Followers Follow Seasoned investor with a deep passion for uncovering high-potential opportunities in the stock market. My analysis combines fundamental analysis, market trends, and strategic insights to deliver actionable investment ideas. Follow me for in-depth analyses, market commentary, and investment strategies designed to help you navigate today's complex financial landscape. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.